Research programme: nociceptin receptor agonists - Astraea Therapeutics
Alternative Names: AT-127; AT-200; AT-326; AT-403Latest Information Update: 28 Apr 2018
Price :
$50 *
At a glance
- Originator Astraea Therapeutics
- Class Opioid analgesics
- Mechanism of Action Nociceptin receptor agonists; Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alcoholism; Dyskinesias; Pain; Substance-related disorders
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for preclinical development in Substance-related disorders in USA
- 28 Jan 2018 No recent reports of development identified for preclinical development in Alcoholism in USA
- 28 Jan 2018 No recent reports of development identified for preclinical development in Dyskinesia in USA